HRP20121074T1 - Derivati kinolina i njihovi farmaceutski sastavi - Google Patents
Derivati kinolina i njihovi farmaceutski sastavi Download PDFInfo
- Publication number
- HRP20121074T1 HRP20121074T1 HRP20121074TT HRP20121074T HRP20121074T1 HR P20121074 T1 HRP20121074 T1 HR P20121074T1 HR P20121074T T HRP20121074T T HR P20121074TT HR P20121074 T HRP20121074 T HR P20121074T HR P20121074 T1 HRP20121074 T1 HR P20121074T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- hydroxy
- indan
- ylamino
- hydroxyethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000013078 crystal Substances 0.000 claims 6
- 229950000339 xinafoate Drugs 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- HZHXFIDENGBQFQ-FTBISJDPSA-N acetic acid;5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound CC(O)=O.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 HZHXFIDENGBQFQ-FTBISJDPSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 230000003326 anti-histaminergic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940015042 glycopyrrolate Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj, naznačen time, da ima formulu I
[image]
u obliku kristalne soli ili kristalnog solvata, gdje je W skupina formule
[image]
i A je acetat ili ksinafoat.
2. Spoj prema zahtjevu 1, naznačen time, da je to kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata.
3. Spoj prema zahtjevu 2, naznačen time, da u svojem uzorku difrakcije X-zraka ima čvrstu vršnu vrijednost (2θ) do 4,3°.
4. Spoj prema zahtjevu 2, naznačen time, da u svojem uzorku difrakcije X-zraka ima sljedeće karakteristične difrakcijske linije (2θ): 4,3 °, 8,4 °, 11,4 °, 15,1 °, 17,0 °, 18,6 °, 19,1 °, 19,7 °, 20,5 °, 22,9 °, 23,3 °, 23,5 °, 24,6 °, 25,6 °, 28,9 ° i 30,5°.
5. Spoj prema zahtjevu 1, naznačen time, da je to kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata.
6. Spoj prema zahtjevu 5, naznačen time, da u svojem uzorku difrakcije X-zraka ima čvrstu vršnu vrijednost (2θ) do 4,1°.
7. Spoj prema zahtjevu 5, naznačen time, da u svojem uzorku difrakcije X-zraka ima sljedeće karakteristične difrakcijske linije (2θ): 4,1 °, 10,0 °, 12,2 °, 12,9 °, 18,2 °, 20,9 ° i 25,9°.
8. Farmaceutski sastav, naznačen time, da kao aktivni sastojak, obuhvaća učinkovitu količinu spoja prema zahtjevu 1, opcijski zajedno s farmaceutski prihvatljivim nosačem.
9. Farmaceutski sastav prema zahtjevu 8, naznačen time, da je aktivni sastojak kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata ili kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata.
10. Farmaceutski sastav prema zahtjevu 8 ili zahtjevu 9, naznačen time, da je u obliku koji se može inhalirati.
11. Farmaceutski sastav prema zahtjevu 8, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jednu, dvije, tri ili više protuupalnih, bronhodilatornih, antihistaminskih/protualergijskih ili antitusivnih ljekovitih tvari.
12. Farmaceutski sastav prema zahtjevu 11, naznačen time, da kao aktivni sastojak, nadalje obuhvaća jedan od spojeva ili oba spoja mometason furoata i glikopirolata.
13. Spoj prema zahtjevu 1, naznačen time, da se upotrebljava za liječenje upalnih ili opstrukcijskih bolesti dišnih puteva.
14. Kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-acetata, naznačen time, da se upotrebljava za liječenje astme ili kronične opstrukcijske plućne bolesti.
15. Kristal (R)-5-[2-(5,6-dietil-indan-2-ilamino)-1-hidroksietil]-8-hidroksi-1H-kinolin-2-on-ksinafoata, naznačen time, da se upotrebljava za liječenje astme ili kronične opstrukcijske plućne bolesti.
16. Postupak proizvodnje spoja prema zahtjevu 1, naznačen time, da obuhvaća:
(i) reakciju slobodne baze s octenom kiselinom, za proizvodnju spojeva formule I, gdje A je acetat; ili
(ii) reakciju slobodne baze s 1-hidroksi 2-naftolnom kiselinom, za proizvodnju spojeva formule I, gdje A je ksinafoat.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0613156A GB0613156D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613159A GB0613159D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| GB0613158A GB0613158D0 (en) | 2006-06-30 | 2006-06-30 | Organic compounds |
| GB0613160A GB0613160D0 (en) | 2006-06-30 | 2006-06-30 | Organic Compounds |
| EP06117129A EP1878722A1 (en) | 2006-07-13 | 2006-07-13 | Quinolinone derivatives and their pharmaceutical compositions |
| PCT/EP2007/056632 WO2008000839A1 (en) | 2006-06-30 | 2007-07-02 | Quinolinone derivatives and their pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121074T1 true HRP20121074T1 (hr) | 2013-01-31 |
Family
ID=38610531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20121074TT HRP20121074T1 (hr) | 2006-06-30 | 2012-12-28 | Derivati kinolina i njihovi farmaceutski sastavi |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8198450B2 (hr) |
| EP (1) | EP2044025B1 (hr) |
| JP (1) | JP5253392B2 (hr) |
| KR (1) | KR101402398B1 (hr) |
| CN (1) | CN101479245B (hr) |
| AU (1) | AU2007264946B2 (hr) |
| BR (1) | BRPI0713951B8 (hr) |
| CA (1) | CA2654801C (hr) |
| CY (3) | CY1113733T1 (hr) |
| DK (1) | DK2044025T3 (hr) |
| ES (1) | ES2396987T3 (hr) |
| FR (2) | FR20C1054I1 (hr) |
| HK (1) | HK1127597A1 (hr) |
| HR (1) | HRP20121074T1 (hr) |
| HU (2) | HUS2000043I1 (hr) |
| IL (1) | IL195796A (hr) |
| LT (2) | LTC2044025I2 (hr) |
| LU (2) | LUC00185I2 (hr) |
| MA (1) | MA30540B1 (hr) |
| MX (1) | MX2008016542A (hr) |
| MY (1) | MY150468A (hr) |
| NO (3) | NO341709B1 (hr) |
| NZ (1) | NZ573292A (hr) |
| PL (1) | PL2044025T3 (hr) |
| PT (1) | PT2044025E (hr) |
| SI (1) | SI2044025T1 (hr) |
| WO (1) | WO2008000839A1 (hr) |
| ZA (1) | ZA200809948B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1860192A1 (en) | 1996-09-17 | 2007-11-28 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating intracellular diseases |
| RU2458925C2 (ru) * | 2007-09-05 | 2012-08-20 | Райджел Фармасьютикалз, Инк. | Ксинафоатная соль n4-[(2,2-дифтор-4н-бензо[1,4]оксазин-3-он)-6-ил]-5-фтор-n2-[3-(метиламинокарбонилметиленокси)фенил]-2,4-пиримидиндиамина |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| AU2014229361B2 (en) | 2013-03-14 | 2016-08-04 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
| US9452139B2 (en) | 2013-03-14 | 2016-09-27 | Novartis Ag | Respirable agglomerates of porous carrier particles and micronized drug |
| EP3347345B1 (en) | 2015-09-29 | 2019-07-31 | Inke, S.A. | Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate |
| CN110724095B (zh) * | 2019-09-12 | 2023-06-09 | 上海方予健康医药科技有限公司 | 一种茚达特罗乙酸盐的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05202301A (ja) * | 1991-08-29 | 1993-08-10 | Yamamoto Chem Inc | ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料 |
| EP0688871A3 (en) * | 1994-06-24 | 1998-07-08 | Quest International B.V. | Preparation of phytosphingosine derivative |
| FR2777279B1 (fr) * | 1998-04-08 | 2004-08-13 | Hoechst Marion Roussel Inc | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| GB0029562D0 (en) * | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0127430D0 (en) | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| US7417051B2 (en) * | 2002-04-12 | 2008-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments comprising betamimetics and a novel anticholinergic |
| US7250426B2 (en) * | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| TWI324150B (en) | 2003-02-28 | 2010-05-01 | Novartis Ag | Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt |
| PE20050211A1 (es) | 2003-04-02 | 2005-04-27 | Novartis Ag | Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas |
| AU2004226824B2 (en) | 2003-04-04 | 2008-05-01 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GB0413960D0 (en) | 2004-06-22 | 2004-07-28 | Novartis Ag | Organic compounds |
| DK1869049T3 (da) | 2005-03-21 | 2009-05-18 | Lilly Co Eli | Imidazopyridazinforbindelser |
| GB0511065D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
-
2007
- 2007-07-02 US US12/304,617 patent/US8198450B2/en active Active
- 2007-07-02 AU AU2007264946A patent/AU2007264946B2/en active Active
- 2007-07-02 KR KR1020087031819A patent/KR101402398B1/ko active IP Right Grant
- 2007-07-02 BR BRPI0713951A patent/BRPI0713951B8/pt active IP Right Grant
- 2007-07-02 MY MYPI20085146 patent/MY150468A/en unknown
- 2007-07-02 EP EP07819899A patent/EP2044025B1/en active Active
- 2007-07-02 PT PT78198991T patent/PT2044025E/pt unknown
- 2007-07-02 PL PL07819899T patent/PL2044025T3/pl unknown
- 2007-07-02 ES ES07819899T patent/ES2396987T3/es active Active
- 2007-07-02 JP JP2009517241A patent/JP5253392B2/ja active Active
- 2007-07-02 DK DK07819899.1T patent/DK2044025T3/da active
- 2007-07-02 CA CA2654801A patent/CA2654801C/en active Active
- 2007-07-02 WO PCT/EP2007/056632 patent/WO2008000839A1/en active Application Filing
- 2007-07-02 CN CN2007800244042A patent/CN101479245B/zh active Active
- 2007-07-02 SI SI200731103T patent/SI2044025T1/sl unknown
- 2007-07-02 NZ NZ573292A patent/NZ573292A/en unknown
- 2007-07-02 MX MX2008016542A patent/MX2008016542A/es active IP Right Grant
-
2008
- 2008-11-24 ZA ZA2008/09948A patent/ZA200809948B/en unknown
- 2008-12-08 IL IL195796A patent/IL195796A/en active IP Right Grant
- 2008-12-30 MA MA31527A patent/MA30540B1/fr unknown
-
2009
- 2009-01-20 NO NO20090312A patent/NO341709B1/no active Protection Beyond IP Right Term
- 2009-07-20 HK HK09106611.7A patent/HK1127597A1/xx unknown
-
2012
- 2012-05-04 US US13/463,978 patent/US20120316142A1/en not_active Abandoned
- 2012-11-29 CY CY20121101169T patent/CY1113733T1/el unknown
- 2012-12-28 HR HRP20121074TT patent/HRP20121074T1/hr unknown
-
2020
- 2020-11-12 FR FR20C1054C patent/FR20C1054I1/fr active Active
- 2020-11-18 HU HUS2000043C patent/HUS2000043I1/hu unknown
- 2020-11-20 LU LU00185C patent/LUC00185I2/fr unknown
- 2020-11-23 NO NO2020041C patent/NO2020041I1/no unknown
- 2020-11-25 LT LTPA2020535C patent/LTC2044025I2/lt unknown
- 2020-11-26 CY CY2020038C patent/CY2020038I1/el unknown
- 2020-12-07 NO NO2020044C patent/NO2020044I1/no unknown
- 2020-12-07 LU LU00188C patent/LUC00188I2/en unknown
- 2020-12-08 FR FR20C1063C patent/FR20C1063I1/fr active Active
- 2020-12-09 HU HUS2000053C patent/HUS2000053I1/hu unknown
- 2020-12-14 CY CY2020041C patent/CY2020041I1/el unknown
- 2020-12-16 LT LTPA2020538C patent/LTPA2020538I1/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121074T1 (hr) | Derivati kinolina i njihovi farmaceutski sastavi | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| AU2018236805B2 (en) | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | |
| HRP20171793T1 (hr) | Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-kloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidroklorid monohidrata | |
| WO2008000483A3 (en) | Phenol derivatives for the treatment of respiratory diseases | |
| JP2011507896A5 (hr) | ||
| SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
| WO2011017201A3 (en) | Dp2 antagonist and uses thereof | |
| JP2011500638A5 (hr) | ||
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| WO2007099553A3 (en) | 1,3-dioxane carboxylic acids | |
| WO2008035359A3 (en) | Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives | |
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| JP2009508916A5 (hr) | ||
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases | |
| WO2008109991A8 (en) | Inhibitors of carnitine palmitoyltransferase and treating cancer | |
| CA2692191C (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
| JP2012523395A5 (hr) | ||
| JP2013538857A5 (hr) | ||
| WO2010129057A3 (en) | Tetracycline compounds | |
| US20070060544A1 (en) | 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use | |
| HRP20120700T1 (hr) | SOLI SPOJEVA INHIBITORA HIV-a | |
| JP2009541455A5 (hr) | ||
| WO2008137809A3 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof |